Fluzone Quadrivalent, the first and only four-strain influenza vaccine option for patients as young as six months of age, according to manufacturer Sanofi Pasteur, has received approval from the FDA.
“Protection against the type B flu strain may be an especially important factor that healthcare providers consider when immunizing children since influenza B causes a substantial number of illnesses, hospitalizations and deaths in the pediatric population,” said David Greenberg, MD, vice president of U.S. Scientific and Medical Affairs for Sanofi Pasteur.
Fluzone Quadrivalent vaccine will be available to U.S. healthcare providers for the 2013-2014 influenza season in prefilled syringes and single-dose vials for intramuscular administration. These presentations of Fluzone Quadrivalent vaccine do not contain preservatives and are not made with natural rubber latex.
